首页> 外文期刊>Annals of surgical oncology >Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
【24h】

Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.

机译:米兰标准以外的肝细胞癌的外科治疗。肝切除,抢救移植和原发性肝移植的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: There is no clear consensus regarding the best treatment strategy for patients with advanced hepatocellular carcinoma (HCC). METHODS: Patients with cirrhosis and HCC beyond Milan who had undergone liver resection (LR) or primary orthotopic liver transplantation (OLT) between November 1995 and December 2005 were included in this study. Pathological tumor staging was based on the American Liver Tumor Study Group modified Tumor-Node-Metastasis classification. RESULTS: A total of 23 HCC patients were primarily treated by means of LR, 5 of whom eventually underwent salvage OLT. An additional 32 patients underwent primary OLT. The overall actuarial survival rates at 3 and 5 years were 35% after LR, and 69% and 60%, respectively, after primary OLT. Recurrence-free survival at 5 years was significantly higher after OLT (65%) than after LR (26%). Of the patients who underwent LR, 11 (48%) experienced HCC recurrence only in the liver; 6 of these 11 presented with advanced HCC recurrence, poor medicalstatus, or short disease-free intervals and were not considered for transplantation. Salvage OLT was performed in 5 patients with early stage recurrence (45% of patients with hepatic recurrence after LR and 22% of all patients who underwent LR). At a median of 18 months after salvage OLT, all 5 patients are alive, 4 are free of disease, and 1 developed HCC recurrence 16 months after salvage OLT. CONCLUSION: For patients with HCC beyond Milan criteria, multimodality treatment-including LR, salvage OLT, and primary OLT-results in long-term survival in half of the patients. When indicated, LR can optimize the use of scarce donor organs by leaving OLT as a reserve option for early stage HCC recurrence.
机译:背景:关于晚期肝细胞癌(HCC)患者的最佳治疗策略尚无明确共识。方法:本研究纳入了1995年11月至2005年12月之间经过肝切除(LR)或原位原位肝移植(OLT)的米兰以外地区的肝硬化和HCC患者。病理肿瘤分期基于美国肝肿瘤研究小组修改的肿瘤结点转移分类。结果:总共23例HCC患者主要通过LR治疗,其中5例最终接受了OLT抢救。另外32名患者接受了原发性OLT。 LR后3年和5年的总精算生存率分别为35%和OLT后的69%和60%。 OLT后(65%)的5年无复发生存率明显高于LR(26%)。接受LR的患者中,有11例(48%)仅在肝中经历了HCC复发;这11例中有6例表现出晚期HCC复发,医疗状况差或无病间隔时间短,因此不考虑进行移植。在5例早期复发患者中进行了挽救性OLT(LR后有肝复发的患者占45%,LR发生的所有患者占22%)。在挽救OLT后18个月的中位数,所有5例患者都还活着,有4名没有疾病,并且1例在挽救OLT后16个月出现了HCC复发。结论:对于超出米兰标准的HCC患者,一半患者采用多模式治疗(包括LR,抢救性OLT和主要OLT)可导致长期生存。指示时,LR可以通过保留OLT作为早期HCC复发的储备选择来优化稀缺供体器官的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号